Ignite Creation Date:
2025-12-25 @ 2:44 AM
Ignite Modification Date:
2026-07-22 @ 9:17 PM
Study NCT ID:
NCT00048633
Status:
COMPLETED
Last Update Posted:
2012-05-23
First Post:
2002-11-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer
Sponsor:
QLT Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
TQD BRST 001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None